Tonlamarsen “suppresses hepatic angiotensinogen production,” Laffin told the media ahead of the late-breaking session. “We know that AGT suppression reduces blood pressure among patients taking zero ...
AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research sessionAcross the COAST 1, ...
Transdermal estradiol offers fewer hot flashes and lower fracture rates, but higher rates of gynecomastia, as it meets the ...
French drugmaker Sanofi said on Friday the European Medicines Agency has recommended the approval of a subcutaneous version ...
After attracting GSK with its subcutaneous delivery tech at the top of the year, South Korea’s Alteogen has snared another ...
The FDA approves Wegovy HD (semaglutide 7.2 mg) for chronic weight management in adults with obesity or overweight and weight-related conditions.
Chugai receives Japanese approval for Lunsumio & Polivy combo therapy for additional indication of relapsed or refractory large B-cell lymphoma: Tokyo Tuesday, March 24, 2026, 11: ...
With low dose starting at 1,290 per month, analysts are expecting a two-fold jump in the sale of GLP-1 units over the next ...
Based on a mean baseline body weight of 248 lb. for Wegovy ® injection 7.2 mg and placebo groups, and 257 lb. for the Wegovy ® 2.4 mg group. * Based on the efficacy estimand: estimated efficacy in an ...
Is it possible to train the body to resist seasonal allergies? That’s the hope promised by a new line of immunotherapy reviving an old treatment.
Dianthus Therapeutics (NASDAQ:DNTH) said it has made an “early go” decision to continue its CAPTIVATE Phase 3 trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results